| Year |
Citation |
Score |
| 2022 |
Napoleon JV, Sagar S, Kubica SP, Boghean L, Kour S, King HM, Sonawane YA, Crawford AJ, Gautam N, Kizhake S, Bialk PA, Kmiec E, Mallareddy JR, Patil PP, Rana S, et al. Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 119: e2115071119. PMID 35476515 DOI: 10.1073/pnas.2115071119 |
0.76 |
|
| 2022 |
Kour S, Rana S, Kubica SP, Kizhake S, Ahmad M, Muñoz-Trujillo C, Klinkebiel D, Singh S, Mallareddy JR, Chandra S, Woods NT, Karpf AR, Natarajan A. Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells. The Journal of Biological Chemistry. 101890. PMID 35378132 DOI: 10.1016/j.jbc.2022.101890 |
0.423 |
|
| 2022 |
Rana S, Kour S, Kizhake S, King HM, Mallareddy JR, Case AJ, Huxford T, Natarajan A. Dimers of isatin derived α-methylene-γ-butyrolactone as potent anti-cancer agents. Bioorganic & Medicinal Chemistry Letters. 65: 128713. PMID 35367592 DOI: 10.1016/j.bmcl.2022.128713 |
0.777 |
|
| 2020 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, et al. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463. PMID 32637035 DOI: 10.18632/Oncotarget.27403 |
0.726 |
|
| 2020 |
Rana S, Kour S, Sonawane YA, Robb CM, Contreras JI, Kizhake S, Zahid M, Karpf AR, Natarajan A. Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design. PMID 32237047 DOI: 10.1111/Cbdd.13684 |
0.767 |
|
| 2019 |
Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855 |
0.747 |
|
| 2019 |
Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters. PMID 30935795 DOI: 10.1016/J.Bmcl.2019.03.035 |
0.781 |
|
| 2018 |
Contreras JI, Robb CM, King HM, Baxter J, Crawford AJ, Kour S, Kizhake S, Sonawane YA, Rana S, Hollingsworth MA, Luo X, Natarajan A. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology. PMID 29608269 DOI: 10.1021/Acschembio.8B00077 |
0.738 |
|
| 2018 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, et al. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232. PMID 29435174 DOI: 10.18632/Oncotarget.23749 |
0.768 |
|
| 2017 |
Robb CM, Contreras JI, Kour S, Taylor MA, Abid M, Sonawane YA, Zahid M, Murry DJ, Natarajan A, Rana S. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications (Cambridge, England). PMID 28636052 DOI: 10.1039/C7Cc03879H |
0.744 |
|
| 2014 |
Khare V, Kour S, Alam N, Dubey RD, Saneja A, Koul M, Gupta AP, Singh D, Singh SK, Saxena AK, Gupta PN. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. International Journal of Pharmaceutics. 470: 51-62. PMID 24810239 DOI: 10.1016/J.Ijpharm.2014.05.005 |
0.466 |
|
| 2013 |
Singh B, Guru SK, Kour S, Jain SK, Sharma R, Sharma PR, Singh SK, Bhushan S, Bharate SB, Vishwakarma RA. Synthesis, antiproliferative and apoptosis-inducing activity of thiazolo[5,4-d]pyrimidines. European Journal of Medicinal Chemistry. 70: 864-74. PMID 24262379 DOI: 10.1016/J.Ejmech.2013.10.039 |
0.339 |
|
| Show low-probability matches. |